Widespread screening for prostate cancer over the past 3 decades using the prostate-specific antigen (PSA) test has led to a flood of men being diagnosed with and treated for prostate cancer that never would have harmed them, according to a new study. The jump in diagnoses was most pronounced among younger men, with rates more than tripling for men aged 50 to 59 and increasing seven-fold for those aged 50 and younger. The study was published online August 31 in the Journal of the National Cancer Institute (JNCI). Read more > >
-
Clinical trial is being planned to test lapatinib in selected patients
-
Trial testing the Gonzalez regimen was one of the first to compare survival following standard or alternative treatments
-
The monoclonal antibody prevented fractures in men receiving common therapy and is under consideration by FDA
-
Finding contradicts past recommendations to avoid the activity
-
Disparate rates may be due to a combination of biological and non-biological factors
Whether treatment is received at a comprehensive cancer center or, as is the case for the majority of patients, at a community hospital, it's unclear who is directing and coordinating the clinical care decisions for those undergoing active treatment. With the expected increase in cancer incidence (due in large part to an aging population), the health care community must begin to focus on this critically important issue.
Read more > >
The director of CDC's National Office of Public Health Genomics discusses the science behind personal genomic tests. These tests, which include "genetic risk profiles" for cancer and other common diseases, are sold directly to consumers.
Read more > >
NCI Cancer Bulletin Articles
in Spanish
Beginning September 15, NCI will publish the Boletín del Instituto Nacional del Cáncer, a modified Spanish-language translation of selected articles previously published in the NCI Cancer Bulletin. This new resource offers Spanish-speaking readers up-to-date articles on the latest research advances in the prevention, treatment, and understanding of cancer. To receive the monthly selection, email nciboletin@mail.nih.gov or view the articles at http://www.cancer.gov/espanol.
-
A new type of cancer drug shows promise in an early stage clinical trial
-
Evidence builds to make a case for palliative care's value, but challenges remain
-
Enthusiasm for this promising therapy may be getting ahead of the research
-
Is the combination of AZD2281 and carboplatin safe for women with
BRCA-related breast or ovarian cancer?
-
- New FDA Center and Advisory Committee Launch Regulation of Tobacco
- Agency Issues New Rules for Obtaining Investigational Drugs
- Dr. William Dahut Named CCR Clinical Director
- NCI Tobacco Control Monograph Addresses Genetics of Nicotine Dependence
- CRCHD Hosted Professional Development and Diversity Training Conference
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
